Skip to content

TMS Treatment for Depression in the National Health Service

An Evaluation of Transcranial Magnetic Stimulation in the National Health Service

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02016456
Acronym
TDEP
Enrollment
29
Registered
2013-12-20
Start date
2014-10-31
Completion date
2017-08-31
Last updated
2017-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Transcranial Magnetic Stimulation, Neuronavigation, Magnetic Resonance Imaging

Brief summary

This research programme purports to test the effectiveness of two Transcranial Magnetic Stimulation (TMS) protocols (Repetitive high frequency protocol and Theta Burst protocol) in reducing the symptoms of depression. The study also uses Magnetic Resonance Imaging (MRI) scans to improve the localization of TMS targets.

Interventions

At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.

Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses

Sponsors

Nottinghamshire Healthcare NHS Trust
CollaboratorOTHER_GOV
Institute of Mental Health Nottingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of depressive disorder (DSM-IV) * Diagnosis of treatment resistance (at least stage 1 as defined by Thase & Rush, 1997 for depression) * Female or male between 18 and 70 years

Exclusion criteria

* History of Bipolar disorder * Clinically relevant neurological comorbidity such as brain neoplasm, cerebral vascular events, epilepsy, neurodegenerative disorders, prior brain surgery * Metal objects in and around body that cannot be removed * Pregnancy * Cardiac pacemaker or implanted medication pump * Major unstable medical illness * Change in prescribed medication in the 2 weeks preceding the start of TMS trial * Current alcohol/stimulant dependence with propensity for toxic/withdrawal seizures

Design outcomes

Primary

MeasureTime frame
Proportion of responders defined as subjects with 50% reduction in the 17-item Hamilton Depression Scale Score4 weeks

Secondary

MeasureTime frame
Mean change in Beck Depression Inventory scores4 weeks

Other

MeasureTime frame
Change in processing speed (using modified digit-symbol test) scores4 weeks and 3 months
Change in Clinical Global Impression scores4 weeks and 3 months
Change in Social and Occupational Functioning Assessment scores4 weeks and 3 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026